Physician profile
Jayna Kelly
NPI 1700229515
$11,095.91
in general payments reported to CMS, 2019-2025
29 companies · $2,888 in 2025
The $2,888 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $201 · 2021: $723 · 2022: $95.10 · 2023: $2,453 · 2024: $4,508 · 2025: $2,888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,862 · Travel and Lodging: $3,988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,861.89 |
| Travel and Lodging | $3,987.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,164.13 | 2022-2025 | Supera, Diamondback Peripheral, Absolute Pro |
| Boston Scientific Corporation | $2,036.56 | 2020-2025 | Watchman Access System, Watchman Flx |
| Medtronic, INC. | $1,163.87 | 2021-2024 | Venaseal, Corevalve Evolut R |
| Abiomed | $995.74 | 2021-2025 | Impella |
| Philips North America LLC | $988.03 | 2023-2024 | (Bi2) Igt Systems Undivided, (Az7) Lasers, (O49) Image Guided Therapy Und |
| Alnylam Pharmaceuticals INC. | $684.60 | 2023-2025 | Amvuttra, Onpattro |
| Becton, Dickinson and Company | $677.83 | 2023-2025 | Rotarexs 6 F X 135 Cm, Lifestent Solo Vascular Stent, Crosser Iq |
| E.R. Squibb & Sons, L.L.C. | $304.89 | 2021-2025 | Camzyos, Eliquis |
| Shockwave Medical, INC | $303.85 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $289.99 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $269.78 | 2019-2022 | |
| Avinger INC. | $196.97 | 2023 | Pantheris |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $184.12 | 2023-2025 | Lifevest |
| Angiodynamics, INC. | $146.52 | 2023-2025 | Auryon Laser System 100-120 Vac, Angiovac |
| United Therapeutics Corporation | $119.78 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $101.11 | 2025 | |
| Novo Nordisk INC | $82.79 | 2025 | |
| Astellas Pharma US INC | $74.19 | 2021 | |
| Amgen INC. | $53.07 | 2021-2025 | Repatha |
| Tactile Systems Technology INC | $46.19 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Esperion Therapeutics, INC. | $36.54 | 2020-2021 | |
| Cvrx, INC. | $35.21 | 2024 | Barostim Neo System |
| Genzyme Corporation | $25.20 | 2025 | |
| Lantheus Medical Imaging, INC. | $24.28 | 2019 | |
| Baxter Healthcare | $23.86 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Bard Peripheral Vascular, INC. | $23.04 | 2025 | Lifestream |
| Lexicon Pharmaceuticals, INC. | $22.08 | 2023 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.04 | 2025 | Jardiance |
| Vivaquant INC, Dba Rhythm Express | $5.65 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayna Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.